Form 4: Pfizer Director Shantanu Narayen Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Director Shantanu Narayen reported the acquisition of phantom stock units in Pfizer, representing deferred director's compensation.
Summary
- On March 28, 2024, Shantanu Narayen, a director of Pfizer Inc., acquired 1,801.802 phantom stock units.
- These units represent deferred director's compensation, including dividend equivalents.
- The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
- The price of the underlying common stock was $27.75.
- Following the transaction, Narayen directly owns 134,402.012 phantom stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding director compensation, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to director compensation and aligns with standard practices for publicly traded companies.
Stakeholder Impact
- The acquisition of phantom stock units by a director may have a minor positive impact on shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 03/28/2024 | Date of transaction: Acquisition of phantom stock units. |
| 04/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.